Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America

Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age,...

Full description

Autores:
Allegri, Ricardo F.
Chrem Méndez, Patricio
Russo, María Julieta
Cohen, Gabriela
Calandri, Ismael Luis
Campos, Jorge A.
Nahas, Federico E.
Surace, Ezequiel I.
Vázquez, Silvia E.
Sevlever, G. E.
Tipo de recurso:
Article of journal
Fecha de publicación:
2018
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/3320
Acceso en línea:
https://hdl.handle.net/11323/3320
https://repositorio.cuc.edu.co/
Palabra clave:
Alzheimer
Amyloid
Biomarker
Mild cognitive impairment
Neurodegeneration
Amiloide
Biomarcador
Deterioro cognitivo leve
Neurodegeneración
Rights
openAccess
License
Attribution-NonCommercial-ShareAlike 4.0 International
id RCUC2_b12451fe14eaa8a264949777da93ba26
oai_identifier_str oai:repositorio.cuc.edu.co:11323/3320
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.spa.fl_str_mv Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
dc.title.translated.spa.fl_str_mv Biomarcadores de enfermedad de Alzheimer en deterioro cognitivo leve: experiencia en una clínica de memoria de Latinoamérica
title Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
spellingShingle Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
Alzheimer
Amyloid
Biomarker
Mild cognitive impairment
Neurodegeneration
Amiloide
Biomarcador
Deterioro cognitivo leve
Neurodegeneración
title_short Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
title_full Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
title_fullStr Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
title_full_unstemmed Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
title_sort Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
dc.creator.fl_str_mv Allegri, Ricardo F.
Chrem Méndez, Patricio
Russo, María Julieta
Cohen, Gabriela
Calandri, Ismael Luis
Campos, Jorge A.
Nahas, Federico E.
Surace, Ezequiel I.
Vázquez, Silvia E.
Sevlever, G. E.
dc.contributor.author.spa.fl_str_mv Allegri, Ricardo F.
Chrem Méndez, Patricio
Russo, María Julieta
Cohen, Gabriela
Calandri, Ismael Luis
Campos, Jorge A.
Nahas, Federico E.
Surace, Ezequiel I.
Vázquez, Silvia E.
Sevlever, G. E.
dc.subject.spa.fl_str_mv Alzheimer
Amyloid
Biomarker
Mild cognitive impairment
Neurodegeneration
Amiloide
Biomarcador
Deterioro cognitivo leve
Neurodegeneración
topic Alzheimer
Amyloid
Biomarker
Mild cognitive impairment
Neurodegeneration
Amiloide
Biomarcador
Deterioro cognitivo leve
Neurodegeneración
description Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age, sex, and educational level) at our memory clinic (Instituto FLENI) in Buenos Aires, Argentina. Patients and controls underwent an extensive demographic, neurological, and neuropsychological assessment. All subjects underwent a brain MRI scan; FDG-PET scan; amyloid PET scan; apolipoprotein E genotyping; and cerebrospinal fluid concentrations of Aβ1-42, tau, and phosphorylated tau. Patients were categorised as positive or negative for the presence of amyloid pathology and neurodegeneration. Results: Amyloid pathology was observed in cerebrospinal fluid results in 18% of controls, 64% of patients with MCI, and 92% of patients with Alzheimer-type dementia. Suspected non–Alzheimer disease pathophysiology was found in 11% of controls, 6% of patients with MCI, and 8% of patients with Alzheimer-type dementia. At 30 months of follow-up, 45% of amyloid-positive patients with MCI and 20% of amyloid-negative patients with MCI showed progression to dementia. Conclusions: This study demonstrates biomarker-based MCI prognosis and supports its role in clinical decision-making in daily practice.
publishDate 2018
dc.date.issued.none.fl_str_mv 2018-04-14
dc.date.accessioned.none.fl_str_mv 2019-05-14T13:06:20Z
dc.date.available.none.fl_str_mv 2019-05-14T13:06:20Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
format http://purl.org/coar/resource_type/c_6501
status_str acceptedVersion
dc.identifier.issn.spa.fl_str_mv 02134853
dc.identifier.uri.spa.fl_str_mv https://hdl.handle.net/11323/3320
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC - Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
identifier_str_mv 02134853
Corporación Universidad de la Costa
REDICUC - Repositorio CUC
url https://hdl.handle.net/11323/3320
https://repositorio.cuc.edu.co/
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.spa.fl_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
http://creativecommons.org/licenses/by-nc-sa/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.publisher.spa.fl_str_mv Universidad de la Costa
institution Corporación Universidad de la Costa
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstreams/1a389e09-b097-432e-bf26-d09c5c769f68/download
https://repositorio.cuc.edu.co/bitstreams/7bfe9fa3-2054-464a-a370-adab0439bb8c/download
https://repositorio.cuc.edu.co/bitstreams/2065c769-163c-4ccd-94cf-bcd370d5425e/download
https://repositorio.cuc.edu.co/bitstreams/00d25772-6e54-481a-9a11-e5ec45290525/download
https://repositorio.cuc.edu.co/bitstreams/c7c9209b-8065-4baf-8cb0-1f7e351e41fe/download
bitstream.checksum.fl_str_mv 724241c63a31ed3e43c0f3461fde9c08
934f4ca17e109e0a05eaeaba504d7ce4
8a4605be74aa9ea9d79846c1fba20a33
0b098906adf8a0c0df5a7a2a54037fe9
b2ffef7c30d7a585a78d64b32e8bcd8a
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio de la Universidad de la Costa CUC
repository.mail.fl_str_mv repdigital@cuc.edu.co
_version_ 1811760750329331712
spelling Allegri, Ricardo F.Chrem Méndez, PatricioRusso, María JulietaCohen, GabrielaCalandri, Ismael LuisCampos, Jorge A.Nahas, Federico E.Surace, Ezequiel I.Vázquez, Silvia E.Sevlever, G. E.2019-05-14T13:06:20Z2019-05-14T13:06:20Z2018-04-1402134853https://hdl.handle.net/11323/3320Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age, sex, and educational level) at our memory clinic (Instituto FLENI) in Buenos Aires, Argentina. Patients and controls underwent an extensive demographic, neurological, and neuropsychological assessment. All subjects underwent a brain MRI scan; FDG-PET scan; amyloid PET scan; apolipoprotein E genotyping; and cerebrospinal fluid concentrations of Aβ1-42, tau, and phosphorylated tau. Patients were categorised as positive or negative for the presence of amyloid pathology and neurodegeneration. Results: Amyloid pathology was observed in cerebrospinal fluid results in 18% of controls, 64% of patients with MCI, and 92% of patients with Alzheimer-type dementia. Suspected non–Alzheimer disease pathophysiology was found in 11% of controls, 6% of patients with MCI, and 8% of patients with Alzheimer-type dementia. At 30 months of follow-up, 45% of amyloid-positive patients with MCI and 20% of amyloid-negative patients with MCI showed progression to dementia. Conclusions: This study demonstrates biomarker-based MCI prognosis and supports its role in clinical decision-making in daily practice.Objetivo: este estudio tuvo como objetivo investigar el papel y el pronóstico de los biomarcadores de la enfermedad de Alzheimer en pacientes con deterioro cognitivo leve (MCI) en una clínica de memoria en América Latina. Métodos: Estudiamos 89 pacientes con LM, 43 con demencia de tipo Alzheimer y 18 controles sanos (emparejados por edad, sexo y nivel educativo) en nuestra clínica de memoria (Instituto FLENI) en Buenos Aires, Argentina. Los pacientes y los controles se sometieron a una extensa evaluación demográfica, neurológica y neuropsicológica. Todos los sujetos se sometieron a una resonancia magnética cerebral; FDG-PET scan; tomografía PET amiloide; apolipoproteína E genotipado; y concentraciones de líquido cefalorraquídeo de Aβ1-42, tau y tau fosforilada. Los pacientes fueron categorizados como positivos o negativos por la presencia de patología amiloide y neurodegeneración. Resultados: se observó patología de amiloide en los resultados del líquido cefalorraquídeo en el 18% de los controles, el 64% de los pacientes con LM y el 92% de los pacientes con demencia de tipo Alzheimer. La sospecha de fisiopatología no relacionada con la enfermedad de Alzheimer se encontró en el 11% de los controles, el 6% de los pacientes con MCI y el 8% de los pacientes con demencia de tipo Alzheimer. A los 30 meses de seguimiento, el 45% de los pacientes con amiloide positivo con MCI y el 20% de los pacientes con amiloide negativo con MCI mostraron progresión a demencia. Conclusiones: este estudio demuestra el pronóstico de MCI basado en biomarcadores y apoya su papel en la toma de decisiones clínicas en la práctica diaria.Allegri, Ricardo F.-32401e5a-217d-458d-846f-9d361c8b020e-0Chrem Méndez, Patricio-e85d4384-3d18-4c2c-b3eb-d4dbc6a2a6a8-0Russo, María Julieta-77886bc5-e0df-4bc1-acfc-7d4a5e5a1dc6-0Cohen, Gabriela-b3a47e48-a3ef-456e-a814-8795b360c90c-0Calandri, Ismael Luis-b614c669-ee2e-467e-8179-1b5cc9badf9b-0Campos, Jorge A.-28d553d5-021d-4ee6-b46e-f3fb496bdae4-0Nahas, Federico E.-22e2f65e-bd51-484d-813d-f396104fc1b8-0Surace, Ezequiel I.-4d93de5d-1bca-4dd0-a400-ec2693b722c0-0Vázquez, Silvia E.-cdd1b025-6bd4-49dd-b074-acd901b2314e-0Sevlever, G. E.-5887388a-0d69-4a9d-9d64-15f5783214a3-0engUniversidad de la CostaAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2AlzheimerAmyloidBiomarkerMild cognitive impairmentNeurodegenerationAmiloideBiomarcadorDeterioro cognitivo leveNeurodegeneraciónBiomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin AmericaBiomarcadores de enfermedad de Alzheimer en deterioro cognitivo leve: experiencia en una clínica de memoria de LatinoaméricaArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersionPublicationORIGINALBIOMARKERS OF ALZHEIMER.pdfBIOMARKERS OF ALZHEIMER.pdfapplication/pdf114938https://repositorio.cuc.edu.co/bitstreams/1a389e09-b097-432e-bf26-d09c5c769f68/download724241c63a31ed3e43c0f3461fde9c08MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81031https://repositorio.cuc.edu.co/bitstreams/7bfe9fa3-2054-464a-a370-adab0439bb8c/download934f4ca17e109e0a05eaeaba504d7ce4MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.cuc.edu.co/bitstreams/2065c769-163c-4ccd-94cf-bcd370d5425e/download8a4605be74aa9ea9d79846c1fba20a33MD53THUMBNAILBIOMARKERS OF ALZHEIMER.pdf.jpgBIOMARKERS OF ALZHEIMER.pdf.jpgimage/jpeg49924https://repositorio.cuc.edu.co/bitstreams/00d25772-6e54-481a-9a11-e5ec45290525/download0b098906adf8a0c0df5a7a2a54037fe9MD55TEXTBIOMARKERS OF ALZHEIMER.pdf.txtBIOMARKERS OF ALZHEIMER.pdf.txttext/plain1850https://repositorio.cuc.edu.co/bitstreams/c7c9209b-8065-4baf-8cb0-1f7e351e41fe/downloadb2ffef7c30d7a585a78d64b32e8bcd8aMD5611323/3320oai:repositorio.cuc.edu.co:11323/33202024-09-17 10:57:45.281http://creativecommons.org/licenses/by-nc-sa/4.0/Attribution-NonCommercial-ShareAlike 4.0 Internationalopen.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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